Influence of aetiology on long-term effects of resynchronization on cardiac structure and function in patients treated with β-blockers

Journal of Cardiovascular Medicine

Volumn 12, Issue 4, 2011, Pages 227-233

  Zacà, Valerio ^a,b   Baiocchi, Claudia ^a   Gaddi, Rosaria ^a   Gentilini, Rodolfo ^a   Lunghetti, Stefano ^a   Padeletti, Margherita ^b   Pagliaro, Antonio ^b   Furiozzi, Fabio ^a   Mondillo, Sergio ^b   Favilli, Roberto ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

blockers; aetiology; cardiac resynchronization therapy; heart failure; remodeling

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BISOPROLOL; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; NEBIVOLOL;

AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE SIZE; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; MORPHOLOGY; RETROSPECTIVE STUDY;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANALYSIS OF VARIANCE; CARDIAC RESYNCHRONIZATION THERAPY; CHI-SQUARE DISTRIBUTION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEART FAILURE; HUMANS; ITALY; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RETROSPECTIVE STUDIES; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 79953669036     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e328343d600     Document Type: Article

References (31)

1. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology, Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388-2442.
2. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al. 2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 119:1977-2016.
3. Vardas PE, Auricchio A, Blanc JJ, Daubert JC, Drexler H, Ector H, et al. European Society of Cardiology; European Heart Rhythm Association. Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. Eur Heart J 2007; 28:2256-2295.
4. McAlister FA, Ezekowitz J, Hooton N, Vandermeer B, Spooner C, Dryden DM, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA 2007; 297:2502-2514.
5. Higgins SL, Hummel JD, Niazi IK, Giudici MC, Worley SJ, Saxon LA, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 2003; 42:1454-1459. (Pubitemid 37267289)
6. St John Sutton MG, Plappert T, Hilpisch KE, Abraham WT, Hayes DL, Chinchoy E. Sustained reverse left ventricular structural remodeling with cardiac resynchronization therapy at one year is a function of etiology: quantitative Doppler echocardiographic evidence from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). Circulation 2006; 113:266-272.
7. Ghio S, Freemantle N, Scelsi L, Serio A, Magrini G, Pasotti M, et al. Longterm left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CARE-HF trial. Eur J Heart Fail 2009; 11:480-488.
8. Wikstrom G, Blomström-Lundqvist C, Andren B, Lönnerholm S, Blomström P, Freemantle N, et al. CARE-HF study investigators. The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial. Eur Heart J 2009; 30:782-788.
9. Di Biase L, Auricchio A, Sorgente A, Civello K, Klersy C, Faletra F, et al. The magnitude of reverse remodelling irrespective of aetiology predicts outcome of heart failure patients treated with cardiac resynchronization therapy. Eur Heart J 2008; 29:2497-2505.
10. Zhang Q, Fung JW, Chan JY, Yip G, Lam YY, Liang YJ, et al. Difference in long-term clinical outcome after cardiac resynchronisation therapy between ischaemic and nonischaemic aetiologies of heart failure. Heart 2009; 95:113-118.
11. Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, et al., Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344:873-880. (Pubitemid 32224395)
12. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al., Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization therapy on morbidity and mortality in heart failure. N Engl J Med 2005; 352:1539-1549.
13. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al., MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361:1329-1338.
14. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al., for the MIRACLE Study Group. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346:1845-1853. (Pubitemid 34603028)
15. Ritter P, Padeletti L, Gillio-Meina L, Gaggini G. Determination of the optimal atrioventricular delay in DDD pacing. Comparison between echo and peak endocardial acceleration measurements. Europace 1999; 1:126-130.
16. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440-1463. (Pubitemid 41821197)
17. Bax JJ, Ansalone G, Breithardt OA, Derumeaux G, Leclercq C, Schalij MJ, et al. Echocardiographic evaluation of cardiac resynchronization therapy: ready for routine clinical use? A critical appraisal. J Am Coll Cardiol 2004; 44:1-9. (Pubitemid 38968446)
18. Quiñones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002; 15:167-184.
19. Tei C, Nishimura RA, Seward JB, Tajik AJ. Noninvasive Doppler derived myocardial performance index: correlation with simultaneous measurements of cardiac catheterization measurements. J Am Soc Echocardiogr 1997; 10:169-178. (Pubitemid 127789844)
20. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 2005; 111:28-49.
21. Auricchio A, Fantoni C, Steinberg JS. Acute and chronic sequelae of ventricular dyssynchrony. Prog Cardiovasc Dis 2006; 48:227-231. (Pubitemid 43326298)
22. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et al., Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme: a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24:442-463.
23. Molhoek SG, Bax JJ, Bleeker GB, Boersma E, van Erven L, Steendijk P, et al. Comparison of response to cardiac resynchronization therapy in patients with sinus rhythm versus chronic atrial fibrillation. Am J Cardiol 2004; 94:1506-1509. (Pubitemid 40268451)
24. Marsan NA, Bleeker GB, van Bommel RJ, Ypenburg C, Delgado V, Borleffs et al. Comparison of time course of response to cardiac resynchronization therapy in patients with ischemic versus nonischemic cardiomyopathy. Am J Cardiol 2009; 103:690-694.
25. van Bommel RJ, Bax JJ, Abraham WT, Chung ES, Pires LA, Tavazzi L, et al. Characteristics of heart failure patients associated with good and poor response to cardiac resynchronization therapy: a PROSPECT (Predictors of Response to CRT) sub-analysis. Eur Heart J 2009; 30:2470-2477.
26. Bellenger NG, Rajappan K, Rahman SL, Lahiri A, Raval U, Webster J, et al., CHRISTMAS Study Steering Committee and Investigators. Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study. Heart 2004; 90:760-764.
27. Gheorghiade M, Sopko G, De Luca L, Velazquez EJ, Parker JD, Binkley PF, et al. Navigating the crossroads of coronary artery disease and heart failure. Circulation 2006; 114:1202-1213. (Pubitemid 44386485)
28. White JA, Yee R, Yuan X, Krahn A, Skanes A, Parker M, et al. Delayed enhancement magnetic resonance imaging predicts response to cardiac resynchronization therapy in patients with intraventricular dyssynchrony. J Am Coll Cardiol 2006; 48:1953-1960. (Pubitemid 44738444)
29. Zacà V, Mondillo S, Gaddi R, Favilli R. Profiling cardiac resynchronization therapy patients: responders, nonresponders and those who cannot respond: the good, the bad and the ugly? Int J Cardiovasc Imaging 2010 [Epub ahead of print].
30. Uemura T, Otsuji Y, Nakashiki K, Yoshifuku S, Maki Y, Yu B, et al. Papillary muscle dysfunction attenuates ischemic mitral regurgitation in patients with localized basal inferior left ventricular remodeling: insights from tissue Doppler strain imaging. J Am Coll Cardiol 2005; 46:113-119. (Pubitemid 40905138)
31. Colucci WS, Kolias TJ, Adams KF, Ghali JK, Gottlieb SS, Greenberg B, et al., REVERT Study Group. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of Ventricular Remodeling with Toprol-XL (REVERT) trial. Circulation 2007; 116:49-56.